Step 1 topics → Gastrointestinal → Hepatitis Antivirals (HBV and HCV)

Hepatitis Antivirals (HBV and HCV)

USMLE Step 1 trap: Confuses HBV treatment (suppressive) with HCV treatment (curative). HBV treatment suppresses viral replication and prevents progression but is not curative; HCV treatment with DAAs is curative.

Hepatitis antivirals split cleanly into two categories on USMLE Step 1: HBV management (suppressive, lifelong) and HCV management (curative, finite course). The exam tests whether you know which drugs are first-line, what the treatment goals actually are, and — critically — which infection can be cured and which cannot. Most questions are straightforward recall or one-step application, but some vignettes will describe a patient who 'completed treatment' and ask you to interpret what that means clinically, which requires understanding the difference between suppression and eradication.

The biggest trap this topic sets is the HBV-vs-HCV cure confusion. Students who learn the drugs in isolation often assume that 'undetectable viral load' after tenofovir or entecavir means the patient is cured — it does not. HBV maintains covalently closed circular DNA (cccDNA) in hepatocyte nuclei that nucleoside analogs cannot clear, so therapy is suppressive and typically lifelong. HCV has no such reservoir, which is why direct-acting antivirals (DAAs) like sofosbuvir-based regimens achieve >95% sustained virologic response, meaning functional cure. USMLE Step 1 will exploit this asymmetry.

A secondary confusion is historical: many resources still mention pegylated interferon and ribavirin for HCV, and some older question banks reflect this. On current exams, DAAs are the answer for HCV. Similarly, lamivudine used to be the HBV go-to, but tenofovir and entecavir are now preferred first-line because their higher genetic barrier to resistance makes them far more reliable long-term. Know these updates — the exam does.

From real student decks
78%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: HBV treatment with nucleoside analogs like tenofovir or entecavir is curative.
Right: HBV treatment suppresses viral replication and prevents progression but is not curative; HCV treatment with DAAs is curative.
Tenofovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block HBV polymerase and suppress viral replication effectively — but they cannot eliminate cccDNA from the nucleus of infected hepatocytes. Because cccDNA persists, stopping therapy almost always leads to viral rebound. Contrast this with HCV, which lacks this nuclear reservoir, so DAAs can clear the virus completely. The phrase 'suppression, not cure' is the key distinction the exam tests.
Common mistake
Wrong: HCV is still primarily treated with pegylated interferon and ribavirin.
Right: HCV is now treated with direct-acting antivirals (DAAs) such as sofosbuvir-based regimens, which achieve >95% cure rates with fewer side effects.
Pegylated interferon plus ribavirin was the standard of care for HCV until approximately 2013–2014, but it has been largely replaced by direct-acting antivirals due to dramatically better efficacy and tolerability. DAA regimens like sofosbuvir/ledipasvir achieve sustained virologic response (functional cure) in over 95% of patients with far fewer side effects than interferon. On USMLE Step 1, if a question asks about current HCV treatment, DAAs are the correct answer — interferon-based regimens are now a historical footnote.
Common mistake
Gap: Missing that HBV treatment goals are suppression and complication prevention, not viral eradication
The goal of chronic HBV treatment is to suppress HBV DNA to undetectable levels, normalize ALT, and prevent cirrhosis and hepatocellular carcinoma, not to eradicate cccDNA.
Students sometimes frame the goal of HBV treatment as 'clearing the virus,' but this sets the wrong expectation. The realistic and testable goals are: suppress HBV DNA to undetectable levels, normalize serum ALT (reflecting reduced hepatic inflammation), and prevent long-term complications including cirrhosis and hepatocellular carcinoma. Eradicating cccDNA is not achievable with current drugs. Knowing these concrete endpoints helps you answer management questions about when to treat and how to monitor.
Common mistake
Wrong: Lamivudine is the preferred first-line agent for chronic HBV.
Right: Tenofovir and entecavir are preferred first-line agents for chronic HBV due to higher barrier to resistance compared to lamivudine.
Lamivudine was an early HBV antiviral but falls out of favor because HBV rapidly develops resistance to it (the YMDD mutation). Tenofovir and entecavir have a much higher genetic barrier to resistance — meaning the virus needs far more simultaneous mutations to escape them — making them safer choices for the long-term suppressive therapy HBV requires. When a question asks which agent to start for chronic HBV, tenofovir or entecavir is correct; lamivudine is the wrong answer.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. For chronic HBV, know the treatment goal (suppress HBV DNA to undetectable, normalize ALT, prevent cirrhosis and hepatocellular carcinoma) and the preferred first-line agents (tenofovir and entecavir), and understand why this therapy is suppressive rather than curative.
  2. For chronic HCV, know that direct-acting antivirals — particularly sofosbuvir-based regimens — have replaced interferon-based therapy and achieve >95% cure rates (sustained virologic response at 12 weeks), making HCV the viral hepatitis that is actually curable with current treatment.

Can you avoid these mistakes?

A 35-year-old man with chronic HBV has been on tenofovir for 3 years with undetectable HBV DNA and normal ALT. He asks if he can stop the medication since his labs are normal. What do you tell him, and why?
A vignette describes a 50-year-old woman with chronic HCV genotype 1 who was treated 10 years ago with pegylated interferon and ribavirin but failed therapy. What would you offer her now, and what outcome can she realistically expect?
A 40-year-old with chronic HBV was started on lamivudine 5 years ago and now has detectable viral rebound. Why is lamivudine no longer preferred as first-line therapy, and what feature of tenofovir or entecavir makes them safer for long-term use?
Two patients are in your clinic: one with chronic HBV on tenofovir, one with chronic HCV who completed a sofosbuvir-based regimen 6 months ago. Which patient is cured, what drug class achieved this, and what is the mechanism that prevents the same outcome in the other patient?

Related topics

Viral Hepatitis Overview (A-E) Gut Tube Regions and Blood Supply Midgut Rotation and Anomalies (Malrotation/Volvulus) Meckel Diverticulum Omphalocele vs Gastroschisis

See how your Anki deck covers this topic.

Upload your deck for a free audit →